A non-surgical breast enhancement procedure using filler derived from cadaver fat has led to serious complications for at least one patient and a legal dispute between the product's manufacturer and New York State health officials. Nicole, a 40-something Californian who requested her privacy be protected, reported developing painful, rock-like lumps and oil cysts in her breasts after undergoing a $10,000 procedure with AlloClae.
AlloClae, introduced in the U.S. in 2024, uses "ethically sourced" donor adipose tissue as an alternative to surgical augmentation. Nicole, who had previously spent nearly $20,000 on unsuccessful fat-grafting procedures, sought AlloClae for a quick, knife-free enhancement. Instead, she described her breasts as feeling like "the surface of the moon" due to the resulting "inoperable bumps and oil cysts."
"I lay down in bed each night and touch the lumps, the pebbles," Nicole told The Post, detailing how the donor-derived filler has led to a "nightmare."
Nicole's experience, while not directly part of the ongoing lawsuit, has fueled her desire for a thorough investigation into the injectable filler. She expressed regret over getting the procedure, which she initially saw as a "miracle" after viewing a plastic surgeon's Instagram post.
Other users have also voiced dissatisfaction online, with some reporting that the product did not last or that they developed recurring cysts after paying significant sums for the treatment. A spokesperson for Tiger Aesthetics, the manufacturer of AlloClae, acknowledged that the product is "not risk-free," stating that "risks associated with any procedure or treatment" apply, including autologous fat transfer. The company added that it cannot comment on individual reports without a full clinical picture but recommended that any new breast lumps or cysts be evaluated by a physician.
Legal Battle Over AlloClae Distribution
Meanwhile, Tiger Aesthetics is engaged in a legal dispute with the New York State Department of Health (DOH). The company sued the DOH, alleging "unlawful and arbitrary" denial of distribution licenses for AlloClae in the state. The DOH, which regulates tissue use and banking in New York, has accused Tiger Aesthetics of attempting to circumvent regulations by "smuggling" the product into the state through indirect means.
Court documents indicate that the DOH accused Tiger Aesthetics of a "scheme to circumvent DOH's prohibition against distributing AlloClae" by shipping the product to residences and businesses in Connecticut and New Jersey, from where it would then be transported into New York. The DOH cited purchase invoices showing shipments to employees of plastic surgeon Dr. Adam Schaffner in Connecticut and New Jersey, and also noted that dozens of boxes of AlloClae were shipped to the home of a New Jersey plastic surgery nurse, Robert McGee, between September 2025 and April 2026. McGee reportedly admitted to transporting the product into New York.
Tiger Aesthetics, however, argues that the state's actions have "disrupted patient care, lost physician trust, damaged market reputation, [and] loss of limbs and life." The company asserts that AlloClae is regulated by the U.S. Food & Drug Administration (FDA) and is legal for sale across all U.S. states. Tiger's spokesperson stated they are in "active and constructive settlement talks with the DOH and [is] confident we will get to a mutually agreeable solution."
Medical Concerns and Regulatory Scrutiny
Dr. Tommaso Addona, a board-certified plastic surgeon, explained that fat necrosis, or the death of fatty tissue, can occur when there is insufficient blood flow to the area where fat is introduced, whether it's the patient's own or donor-derived. While these growths are typically noncancerous, they can cause complications, including the need for more frequent imaging and potential biopsies, which can be challenging for radiologists to interpret if they are unfamiliar with the filler.
Nicole's medical imaging revealed masses that radiologists identified as "oversized granulomas," which partially obscure evaluations and make it difficult to distinguish between noncancerous and potentially malignant lumps. She noted that some medical professionals are unfamiliar with AlloClae, making it difficult for them to provide assistance.
Nicole hopes that her experience will lead to increased research and regulatory scrutiny of AlloClae. Despite her ongoing physical and emotional distress, with palpable lumps remaining in her breasts, she stated, "I'll never be 100% lump free."